BREAKING NEWS: SINTX Technologies, Inc. has just signed a groundbreaking supply agreement with Evonik Corporation to accelerate the production of its proprietary silicon nitride–PEEK compound (SiN/PEEK) for AI-assisted, 3D-printed patient-specific implants. This agreement, announced today, enables immediate manufacturing at SINTX’s facility in Salt Lake City, Utah, marking a significant leap forward in customized medical solutions.
The new partnership allows SINTX to leverage Evonik’s commercial-scale production capabilities to fulfill increasing demands for innovative medical devices. With this supply agreement in place, SINTX is set to begin producing customized implants tailored to the unique needs of patients, including those requiring humanitarian-use vertebral body replacements following tumor resections.
Eric K. Olson, Chairman, President & CEO of SINTX, emphasized the importance of this development, stating, “This agreement with Evonik is another pivotal moment for SINTX and for the field of patient-specific implants.” He highlighted how the combination of SINTX’s silicon nitride biomaterial and Evonik’s polymer manufacturing expertise will address critical needs in trauma, spine, oncology, and beyond.
Physicians have already requested the innovative implants, underscoring the urgent demand for solutions that support complex surgical procedures. The SiN/PEEK compound not only aids in patient-specific designs but also features antipathogenic properties that combat infection risks—a crucial advantage in high-stakes surgeries.
In addition to addressing immediate medical needs, SINTX plans to utilize the SiN/PEEK compound to facilitate regulatory clearances for both patient-matched and traditionally manufactured implantable devices. This strategic move positions SINTX at the forefront of medical innovation, with the potential to transform patient treatment protocols.
Marc Knebel, head of Evonik’s Medical Devices & Systems market segment, expressed enthusiasm about the partnership. He stated, “We are excited to support SINTX in bringing a high-performance SiN/PEEK composite filament to market for additive and subtractive manufacturing of regulated medical devices.” The collaboration promises consistent quality, supply reliability, and scalability, essential for meeting the diverse needs of the medical device market.
The SiN/PEEK combination is designed to deliver enhanced clinical outcomes through its unique properties: it reduces microbial adherence, promotes bone integration, and improves visualization during surgical procedures. These features are vital for surgeons who require precision and reliability when operating in challenging anatomical environments.
As SINTX focuses on humanitarian efforts, particularly in trauma and oncology cases, the company is also preparing to expand its regulatory framework and production capabilities to encompass a broader range of medical indications. Dr. Ryan Bock, SINTX Chief Technology Officer, stated, “We’re responding to real-world surgeon requests in oncology-related care,” highlighting the company’s commitment to meeting urgent healthcare needs.
This supply agreement is not just a business milestone; it represents a significant advancement in the field of patient-specific implants, with potential benefits that could reshape surgical practices and improve outcomes for countless patients.
For more information about SINTX Technologies and its innovative materials platform, visit www.sintx.com.
Stay tuned as we continue to monitor this developing story and its impact on the medical device industry.
